

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2022

Allena Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-38268
(Commission File Number)

45-2729920
(IRS Employer
Identification No.)

**One Newton Executive Park
Suite 202
Newton, Massachusetts**
(Address of Principal Executive Offices)

02462
(Zip Code)

Registrant's Telephone Number, Including Area Code: (617) 467-4577

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ALNA	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.02 Termination of a Material Definitive Agreement.

On June 15, 2022, Allena Pharmaceuticals, Inc. (the “Company”) delivered written notice to terminate its Commercial Lease (the “Lease”) with Cummings Properties, LLC (the “Lessor”), under which the Company currently occupies approximately 6,055 square feet of office space at One Newton Executive Park, Suite 202, in Newton, Massachusetts, which is currently the location of the Company’s principal executive offices. The Lease will terminate effective July 31, 2022.

Beginning on August 1, 2022, the Company’s principal executive offices will be located at 142-F North Road, Suite 150, Sudbury, Massachusetts 01776.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Allena Pharmaceuticals, Inc.

Date: June 22, 2022

By: /s/ Richard Katz
Richard Katz, M.D.
Chief Financial Officer
